White Knight Strategic Wealth Advisors LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,637 shares of the medical research company’s stock after selling 39 shares during the quarter. White Knight Strategic Wealth Advisors LLC’s holdings in Amgen were worth $850,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Old Port Advisors lifted its holdings in shares of Amgen by 4.3% during the 1st quarter. Old Port Advisors now owns 1,162 shares of the medical research company’s stock worth $330,000 after acquiring an additional 48 shares during the period. Jackson Wealth Management LLC acquired a new stake in shares of Amgen during the second quarter worth $1,026,000. Transcend Capital Advisors LLC boosted its stake in Amgen by 3.8% in the second quarter. Transcend Capital Advisors LLC now owns 11,107 shares of the medical research company’s stock valued at $3,471,000 after acquiring an additional 404 shares during the period. Davis Capital Management grew its position in shares of Amgen by 1.1% during the second quarter. Davis Capital Management now owns 5,791 shares of the medical research company’s stock worth $1,801,000 after acquiring an additional 61 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Amgen by 109.8% in the 2nd quarter. GAMMA Investing LLC now owns 8,290 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 4,338 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.
Amgen Price Performance
Shares of AMGN opened at $282.87 on Friday. The firm’s 50 day moving average price is $311.37 and its 200 day moving average price is $317.14. Amgen Inc. has a twelve month low of $257.80 and a twelve month high of $346.85. The firm has a market cap of $152.05 billion, a PE ratio of 36.22, a PEG ratio of 2.50 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.
Amgen Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio is 115.24%.
Wall Street Analysts Forecast Growth
AMGN has been the topic of several analyst reports. Bank of America raised their target price on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and increased their price objective for the company from $320.00 to $333.00 in a report on Monday, October 14th. Leerink Partners cut their target price on Amgen from $349.00 to $302.00 in a research report on Wednesday. Finally, Citigroup dropped their price objective on Amgen from $335.00 to $310.00 in a research note on Wednesday. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $323.05.
Check Out Our Latest Stock Analysis on Amgen
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
- Five stocks we like better than Amgen
- What Are Dividend Champions? How to Invest in the Champions
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 11/25 – 11/29
- How to Find Undervalued Stocks
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.